share_log

Silence Therapeutics Seeks Approval to Cancel AIM Trading

Dow Jones Newswires ·  Oct 15, 2021 14:40

By Ian Walker

Silence Therapeutics PLC said Friday that it is seeking shareholder approval to cancel its listing on London's junior AIM, keeping a single listing on New York's Nasdaq.

The medical company said delisting from AIM will enhance liquidity in its American Depositary Shares and increase U.S. investors' willingness to invest in the company.

If approved by shareholders at a general meeting on Nov. 1, the last trading day on AIM is expected to be Nov. 29, it said.

Write to Ian Walker at ian.walker@wsj.com

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment